Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners

Research analysts at Leerink Partners initiated coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK) in a research report issued to clients and investors on Monday. The firm set an “outperform” rating and a $9.00 price target on the stock. Leerink Partners’ price objective would indicate a potential upside of 126.70% from the stock’s current price.

Several other equities research analysts have also commented on the stock. B. Riley Financial assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday, June 25th. They issued a “buy” rating and a $10.00 price target on the stock. Oppenheimer reiterated an “outperform” rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings downgraded Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Finally, Citigroup started coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.20.

Whitehawk Therapeutics Stock Performance

Shares of WHWK opened at $3.97 on Monday. The firm has a fifty day moving average of $4.28 and a 200-day moving average of $3.61. The company has a market cap of $196.32 million, a price-to-earnings ratio of -2.36 and a beta of 0.77. Whitehawk Therapeutics has a 1 year low of $1.57 and a 1 year high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. Analysts predict that Whitehawk Therapeutics will post -1.37 EPS for the current year.

Insider Activity at Whitehawk Therapeutics

In related news, insider Bryan Ball sold 92,460 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $3.64, for a total value of $336,554.40. Following the sale, the insider directly owned 397,106 shares in the company, valued at $1,445,465.84. The trade was a 18.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Scott M. Giacobello sold 141,600 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $4.13, for a total transaction of $584,808.00. Following the sale, the chief financial officer directly owned 295,224 shares of the company’s stock, valued at approximately $1,219,275.12. This represents a 32.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 311,060 shares of company stock worth $1,218,582 in the last ninety days. Corporate insiders own 49.90% of the company’s stock.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Quadrature Capital Ltd bought a new stake in shares of Whitehawk Therapeutics during the 4th quarter worth $28,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Whitehawk Therapeutics during the first quarter worth $40,000. Dimensional Fund Advisors LP purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at $84,000. Squarepoint Ops LLC purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at $159,000. Finally, Marshall Wace LLP purchased a new stake in shares of Whitehawk Therapeutics during the fourth quarter valued at $164,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.